Prognostic value of serum albumin level in patients with diffuse large B cell lymphoma.

IF 1.4 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Acta biochimica Polonica Pub Date : 2023-12-05 DOI:10.18388/abp.2020_6171

Liyan Chen, Lili Pan, Tingbo Liu

{"title":"Prognostic value of serum albumin level in patients with diffuse large B cell lymphoma.","authors":"Liyan Chen, Lili Pan, Tingbo Liu","doi":"10.18388/abp.2020_6171","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the prognostic value of serum albumin (SA) levels before chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) after receiving chemotherapy.Methods: This is a retrospective study, and 127 patients with DLBCL including 71 males (55.9%) and 56 females (44.1%) were included. Patients' gender, age, Ann Arbor staging, eastern cooperative oncology group (ECOG) score, treatment options, international prognostic index, response rate, overall survival (OS), and progression-free survival (PFS) were obtained for statistical analysis.Results: Univariate analysis showed that SA≤34 g/L, Ann Arbor III-IV, B symptoms, ECOG≥2, and bone marrow involvement suggest a poor prognosis in patients with DLBCL. Patients with persistent SA>34 g/L had significantly longer OS than patients with persistent SA≤34 g/L (P=0.020). Multivariate analysis showed that SA≤34 g/L (HR=0.48, 95% CI=0.26-0.90, P=0.022) and R-CHOP-like treatment regimen (HR=0.43, 95% CI=0.24-0.76, P=0.004) are independent factors that could affect the prognosis of patients with DLBCL.Conclusion: SA can be used as an indicator of prognosis in patients with DLBCL before the first chemotherapy. DLBCL patients with SA≤34 g/L are associated with short OS and poor prognosis, which may potentially provide guidance for the clinician to pay more attention to this population before the first chemotherapy.","PeriodicalId":6984,"journal":{"name":"Acta biochimica Polonica","volume":" ","pages":"767-776"},"PeriodicalIF":1.4000,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta biochimica Polonica","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.18388/abp.2020_6171","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the prognostic value of serum albumin (SA) levels before chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) after receiving chemotherapy.

Methods: This is a retrospective study, and 127 patients with DLBCL including 71 males (55.9%) and 56 females (44.1%) were included. Patients' gender, age, Ann Arbor staging, eastern cooperative oncology group (ECOG) score, treatment options, international prognostic index, response rate, overall survival (OS), and progression-free survival (PFS) were obtained for statistical analysis.

Results: Univariate analysis showed that SA≤34 g/L, Ann Arbor III-IV, B symptoms, ECOG≥2, and bone marrow involvement suggest a poor prognosis in patients with DLBCL. Patients with persistent SA>34 g/L had significantly longer OS than patients with persistent SA≤34 g/L (P=0.020). Multivariate analysis showed that SA≤34 g/L (HR=0.48, 95% CI=0.26-0.90, P=0.022) and R-CHOP-like treatment regimen (HR=0.43, 95% CI=0.24-0.76, P=0.004) are independent factors that could affect the prognosis of patients with DLBCL.

Conclusion: SA can be used as an indicator of prognosis in patients with DLBCL before the first chemotherapy. DLBCL patients with SA≤34 g/L are associated with short OS and poor prognosis, which may potentially provide guidance for the clinician to pay more attention to this population before the first chemotherapy.

查看原文本刊更多论文

弥漫大 B 细胞淋巴瘤患者血清白蛋白水平的预后价值。

目的研究弥漫大B细胞淋巴瘤（DLBCL）患者化疗前血清白蛋白（SA）水平对化疗后预后的影响：这是一项回顾性研究，共纳入127例DLBCL患者，其中男性71例（55.9%），女性56例（44.1%）。结果：单变量分析表明，SA.A.与SA.B.A.的差异为0.05%，SA.A.与SA.B.的差异为0.05%，SA.B.A.与SA.B.A.的差异为0.05%：单变量分析显示，SA≤34 g/L、Ann Arbor III-IV、B症状、ECOG≥2和骨髓受累提示DLBCL患者预后不良。SA＞34 g/L持续存在的患者的OS明显长于SA≤34 g/L持续存在的患者（P=0.020）。多变量分析显示，SA≤34 g/L（HR=0.48，95% CI=0.26-0.90，P=0.022）和R-CHOP类治疗方案（HR=0.43，95% CI=0.24-0.76，P=0.004）是影响DLBCL患者预后的独立因素：结论：SA可作为DLBCL患者首次化疗前的预后指标。结论：SA可作为DLBCL患者首次化疗前的预后指标，SA≤34 g/L的DLBCL患者OS短、预后差，这可能为临床医生在首次化疗前更多地关注这一人群提供指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta biochimica Polonica 生物-生化与分子生物学

CiteScore

2.40

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Acta Biochimica Polonica is a journal covering enzymology and metabolism, membranes and bioenergetics, gene structure and expression, protein, nucleic acid and carbohydrate structure and metabolism.